Prognostic value of neuroendocrine serum markers and PSA in irradiated patients with pN0 localized prostate cancer

Prostate

Volumn 46, Issue 2, 2001, Pages 126-133

  Lilleby, Wolfgang ^a   Paus, Elisabeth ^a   Skovlund, Eva ^a   Fosså, Sophie D ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Neuroendocrine serum markers; Prostate cancer; Radiation treatment

Indexed keywords

CHROMOGRANIN A; NEURON SPECIFIC ENOLASE; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ARTICLE; CANCER GRADING; CANCER LOCALIZATION; CANCER STAGING; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; ENZYME ACTIVITY; FROZEN SECTION; HUMAN; HUMAN CELL; IRRADIATION; MALE; MULTIVARIATE ANALYSIS; NEUROENDOCRINE DISEASE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; RADIOTHERAPY; RISK FACTOR;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; CHROMOGRANIN A; CHROMOGRANINS; DISEASE-FREE SURVIVAL; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PHOSPHOPYRUVATE HYDRATASE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 0035253571     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0045(20010201)46:2<126::AID-PROS1016>3.0.CO;2-7     Document Type: Article

References (38)

1. Cancer statistics, 1999
2. The effect of dose on local control of prostate cancer
3. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin
4. Prostate Cancer Clinical Guidelines Panel Summary report on the management of clinically localized prostate cancer
5. Potency, continence and complication rates in 1,870 consecutive radical retropubic prostatectomies
6. Assessing the variability of outcome for patients treated with localized prostate irradiation using different definitions of biochemical control
7. Histopathology of localized prostate cancer. Consensus Conference on Diagnosis and Prognostic Parameters in Localized Prostate Cancer. Stockholm, Sweden, May 12-13, 1993
8. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update
9. Immunoassay and immunohistology studies of chromo-graninA as a neuroendocrine marker in patients with carcinoma of the prostate
10. Neuroendocrine differentiation in prostate cancer: Enhanced prediction of progression after radical prostatectomy
11. Zur Frage der Endokrinie der menschlichen Vorsteherdrüse
12. Neuroendocrine differentiation in prostatic malignancy
13. Neuroendocrine differentiation in metastatic prostatic adenocarcinoma
14. Neurogenic origin of human prostate endocrine cells
15. Neuroendocrine differentiation in human prostatic tumor models
16. Cell kinetics of prostate exocrine and neuroendocrine epithelium and their differential interrelationship: New perspectives
17. Neutral endopeptidase 24.11 loss in metastatic human prostate cancer contributes to androgen-independent progression
18. The prognostic value of neuroendocrine differentiation in adenocarcinoma of the prostate in relation to progression of disease after endocrine therapy
19. The prognostic influence of neuroendocrine cells in prostate cancer: Results of a long-term follow-up study with patients treated by radical prostatectomy
20. Plasma neuroendocrine markers in patients with benign prostatic hyperplasia and prostatic carcinoma
21. Neuroendocrine differentiation and prognosis in prostatic adenocarcinoma
22. The correlation between the ASTRO Consensus Panel definition of biochemical failure and clinical outcome for patients with prostate cancer treated with external beam irradiation
23. Histological typing of prostate tumours
24. Stability of free and total prostate specific antigen in serum from patients with prostate carcinoma and benign hyperplasia
25. Immunoradiometric assay for alpha gamma- and gamma gamma-enolase (neuron-specific enolase), with use of monoclonal antibodies and magnetizable polymer particles
26. Expression and interconversion of neuron-specific enolase in patient sera and extracts from small-cell lung cancer cells
27. A new human chromogranin A (CgA) immunoradiometric assay involving monoclonal antibodies raised against the unprocessed central domain (145-245)
28. Neuroendocrine differentiation in prostatic carcinoma: An update
29. Evaluation and clinical value of neuroendocrine differentiation in human prostatic tumors
30. Neuroendocrine differentiation in renal cell carcinoma - Evaluation of chromogranin A and neuron-specific enolase
31. Prostatic carcinoma: Histological and immunohistological factors affecting prognosis
32. Prognostic significance of neuroendocrine differentiation in clinically localized prostatic carcinoma
33. Elevated plasma chromogranin-A concentrations in prostatic carcinoma
34. Neuroendocrine differentiation in carcinomas of the prostate: Do neuroendocrine serum markers reflect immunohistochemical findings?
35. Neuroendocrine (NE) differentiation as a prognostic indicator in locally advanced prostate cancer (PCa)
36. Neuroendocrine differentiation in prostatic adenocarcinoma is not an independent prognostic indicator
37. Update on the treatment of prostate cancer with external beam irradiation
38. Conventional external-beam radiation therapy alone or with androgen ablation for clinical stage III (T3, NX/N0, M0) adenocarcinoma of the prostate